Miller Rachel L, Grayson Mitchell H, Strothman Kasey
Division of Clinical Immunology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Division of Allergy and Immunology, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio; Center for Clinical and Translational Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio.
J Allergy Clin Immunol. 2021 Dec;148(6):1430-1441. doi: 10.1016/j.jaci.2021.10.001. Epub 2021 Oct 14.
The last 2 years yielded a proliferation of high-quality asthma research. These include new understandings of the incidence and natural history of asthma, findings on the effects of exposure to air pollution, allergens, and intake of acetaminophen, soy isoflavones, and polyunsaturated fatty acids, and exposure to microbial products. The past 2 years have benefited from great strides in determining potential mechanisms of asthma development and asthma exacerbations. These novel understandings led to identification and development of exciting new avenues for potential therapeutic intervention. Finally, there has been significant progress made in the development of tools to facilitate the diagnosis of asthma and measurement of airway physiology and in precision diagnostic approaches. Asthma guidelines were updated and new insights into the pharmacologic management of patients, including biologics, were reported. We review the most notable advances in the natural history of asthma, risk factors for the development of asthma, underlying mechanisms, diagnostic approaches, and treatments. Although greater knowledge of the mechanisms underlying responses and nonresponses to novel therapeutics and across asthma phenotypes would be beneficial, the progress over just the past 2 years has been immense and impactful.
过去两年涌现出大量高质量的哮喘研究成果。这些成果包括对哮喘发病率和自然史的新认识、关于接触空气污染、过敏原以及服用对乙酰氨基酚、大豆异黄酮和多不饱和脂肪酸以及接触微生物产物影响的研究发现。过去两年在确定哮喘发展和哮喘加重的潜在机制方面取得了巨大进展。这些新认识促使人们识别并开发出令人兴奋的潜在治疗干预新途径。最后,在开发有助于哮喘诊断、气道生理学测量的工具以及精准诊断方法方面取得了重大进展。哮喘指南得到更新,并且报告了对患者药物治疗管理(包括生物制剂)的新见解。我们回顾了哮喘自然史、哮喘发展的风险因素、潜在机制、诊断方法和治疗方面最显著的进展。尽管对新疗法以及不同哮喘表型的反应和无反应背后机制有更多了解会很有帮助,但仅在过去两年里就取得了巨大且有影响力的进展。